Skip to main content
SpringerLink
Log in

In Vitro Drug Release Testing of Veterinary Pharmaceuticals

  • Chapter
  • First Online:
Long Acting Animal Health Drug Products

Part of the book series: Advances in Delivery Science and Technology ((ADST))

Abstract

In vitro drug release testing for veterinary pharmaceuticals is a regulatory requirement to aid in the understanding of the in vivo performance of a dosage form. The in vitro release test is used throughout development for formulation and process characterization and post-approval to ensure product quality and therapeutic effect. The current recommended in vitro test equipment and conditions are better suited for mimicking human gastric system physiology but not that of the patients being dosed with veterinary pharmaceuticals. Veterinary dosage forms and delivery systems tend to be more complex and varied because of the diversity of species, size of the animals, and prevalence of unconventional excipients often not used in human health drug products. Therefore, the development of in vitro release tests specific for use with veterinary medicines can be challenging and unconventional with respect to the expectations from the regulatory agencies. Regardless of the analytical approach to development, the final in vitro release test is expected to be ­discriminating with respect to the impact of critical quality attributes on in vivo behavior and easily performed in quality control environments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. United States Pharmacopeia 34—National Formulary 29 (2011) <1088> In vitro and in vivo evaluation of dosage forms. United States Pharmacopeia Convention, Rockville, MD, pp 612–617

    Google Scholar 

  2. United States Pharmacopeia 34—National Formulary 29 (2011) <711> Dissolution. United States Pharmacopeia Convention, Rockville, MD, pp 278–284

    Google Scholar 

  3. Siewart M, Dressman J, Brown C, Shah V (2003) FIP/AAPS guidelines for dissolution/in vitro release testing of novel/special dosage forms. Dissolution Technol 10(1):6–15

    Article  Google Scholar 

  4. Brown WE (2005) Compendial requirements of dissolution testing – European pharmacopoeia, United States pharmacopeia. In: Dressman J, Krämer J (eds) Pharmaceutical Dissolution Testing, 1st edn. Taylor & Francis, New York pp, pp 69–80

    Chapter  Google Scholar 

  5. Kramer J, Grady LT, Gajendran J (2005) Historical development of dissolution testing. In: Dressman J, Krämer J (eds) Pharmaceutical Dissolution Testing, 1st edn. Taylor & Francis, New York pp, pp 1–37

    Google Scholar 

  6. Abdou HM (1989) Mechanism of drug absorption. In: Gennaro A, Migdalof B, Hassert GL, Medwick T (eds) Dissolution, Bioavailability, and Bioequivalence, 1st edn. Mack Publishing Company, Pennsylvania pp, pp 303–314

    Google Scholar 

  7. Martinez M, Amidon G, Clarke L, Jones WW, Mitra A, Riviere J (2002) Applying the biopharmaceutics classification system to veterinary pharmaceutical products, part II: physiological considerations. Adv Drug Deliv Rev 54:825–850

    Article  CAS  PubMed  Google Scholar 

  8. United States Food and Drug Administration (2000) Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Center for Drug Evaluation and Research (CDER), Rockville, MD

    Google Scholar 

  9. Reddy BB, Karunakar A (2011) Biopharmaceutics classification system: a regulatory approach. Dissolution Technol 18(1):31–37

    Article  Google Scholar 

  10. Martinez M, Augsburger L, Johnston T, Jones WW (2002) Applying the biopharmaceutics classification system to veterinary pharmaceutical products, part I: biopharmaceutics and formulation considerations. Adv Drug Deliv Rev 54:805–824

    Article  CAS  PubMed  Google Scholar 

  11. Parker J, Gray V (2006) Highlights of the AAPS workshop on dissolution testing for the 21st Century. Dissolution Technol 13(3):26–31

    Article  Google Scholar 

  12. D’Souza SS, Lozano R, Mayock S, Gray V (2010) AAPS workshop on the role of dissolution in QbD and drug product life cycle: a commentary. Dissolution Technol 17(4):41–45

    Article  Google Scholar 

  13. United States Food and Drug Administration (1997) Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. Center for Drug Evaluation and Research (CDER), Rockville, MD

    Google Scholar 

  14. Brown CK (2005) Dissolution method development: an industry perspective. In: Dressman J, Krämer J (eds) Pharmaceutical Dissolution Testing, 1st edn. Taylor & Francis, New York pp, pp 351–372

    Chapter  Google Scholar 

  15. Gray VA (2005) Compendial testing equipment: calibration, qualification, and sources of error. In: Dressman J, Krämer J (eds) Pharmaceutical dissolution testing, 1st edn. Taylor & Francis, New York, pp 39–67

    Chapter  Google Scholar 

  16. European Pharmacopoeia 7.0 (2011) 2.9.4 Dissolution test for transdermal patches: 263–265

    Google Scholar 

  17. European Pharmacopoeia 7.0 (2011) 2.9.25 Dissolution test for medicated chewing gums: 289–290

    Google Scholar 

  18. European Pharmacopoeia 7.0 (2011) 2.9.42 Dissolution test for lipophilic solid dosage forms: 319–321

    Google Scholar 

  19. Rohrs BR, Burch-Clark DL, Witt MJ (1995) USP dissolution apparatus 3 (reciprocating cylinder): instrument parameters effects on drug release from sustained release formulations. J Pharm Sci 84:922–926

    Article  CAS  PubMed  Google Scholar 

  20. Lonney TJ (1996) USP apparatus 4 (flow through method) primer. Dissolution Technol 3(2):10–12

    Article  Google Scholar 

  21. Emami J (2006) In vitro-in vivo correlation: from theory to applications. J Pharm Sci 9(2):31–51

    Google Scholar 

  22. Abdou HM (1989) Theory of dissolution. In: Gennaro A, Migdalof B, Hassert GL, Medwick T (eds) Dissolution, bioavailability, and bioequivalence, 1st edn. Mack Publishing Company, Easton, PA, pp 11–36

    Google Scholar 

  23. United States Pharmacopeia 34—National Formulary 29 (2011) <1092> The dissolution procedure. United States Pharmacopeia Convention, Rockville, MD, pp 624–630

    Google Scholar 

  24. European Pharmacopoeia 7.0 (2011) 5.17.1 Recommendations on dissolution testing: 665–667

    Google Scholar 

  25. Marques M (2004) Dissolution media simulating fasted and fed states. Dissolution Technol 11(2):16

    Article  Google Scholar 

  26. Baggot JD, Brown SA (2010) Basis for selection of the dosage form. In: Hardee GE, Baggot JD (eds) Development and formulation of veterinary dosage forms, vol 88, Drugs and the Pharmaceutical Sciences. Informa Healthcare, New York, pp 7–144

    Google Scholar 

  27. Fleischer S, Sharkey M, Mealey K, Ostrander EA, Martinez M (2008) Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS J 10(1):110–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Martinez MN, Papich MG (2009) Factors influencing the gastric residence of dosage forms in dogs. J Pharm Sci 98(3):844–860

    Article  CAS  PubMed  Google Scholar 

  29. Sagawa K, Fasheng L, Liese R, Sutton SC (2009) Fed and fasted gastric pH and gastric residence time in conscious Beagle dogs. J Pharm Sci 98(7):2494–2500

    Article  CAS  PubMed  Google Scholar 

  30. Sutton SC (2004) Companion animal physiology and dosage form performance. Adv Drug Deliv Rev 56:1383–1398

    Article  CAS  PubMed  Google Scholar 

  31. Vandamme TF, Ellis KJ (2004) Issues and challenges in developing ruminal drug delivery systems. Adv Drug Deliv Rev 56:1415–1436

    Article  CAS  PubMed  Google Scholar 

  32. Wu SHW, Papas A (1997) Rumen-stable delivery systems. Adv Drug Deliv Rev 28:323–334

    Article  CAS  PubMed  Google Scholar 

  33. Fahmy R, Marnane W, Bensley D, Hollenbeck RG (2002) Dissolution test development for complex veterinary dosage forms: oral boluses. AAPS Pharm Sci 4(4):1–8

    Article  Google Scholar 

  34. Fahmy R, Marnane W, Bensley D, Hollenbeck RG (2001) Dissolution testing of veterinary products: dissolution testing of aspirin boluses. Dissolution Technol 8(1):1–4

    Article  Google Scholar 

  35. Fahmy R, Marnane W, Bensley D, Hollenbeck RG (2001) Dissolution testing of veterinary products: dissolution testing of tetracycline boluses. Dissolution Technol 8(1):1–3

    Article  Google Scholar 

  36. Zingerman JR, Cardinal JR, Chern RT, Holste J, Williams JB, Eckenhoff B, Wright J (1997) The in vitro and in vivo performance of an osmotically controlled delivery system—IVOMEC SR® bolus. J Control Release 47:1–11

    Article  CAS  Google Scholar 

  37. Brown CK, Friedel HD, Barker AR, Buhse LF, Keitel S, Cecil TL, Kraemer J, Morris JM, Reppas C, Stickelmeyer MP, Yomota C, Shah VP (2011) FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms. AAPS Pharm Sci Technol 12(2):782–794

    Article  CAS  Google Scholar 

  38. Martinez M, Rathbone M, Burgess D, Huynh M (2008) In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 129:79–87

    Article  CAS  PubMed  Google Scholar 

  39. Iyer SS, Barr WH, Karnes TH (2006) Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug development. Biopharm Drug Dispos 27(4):157–170

    Article  CAS  PubMed  Google Scholar 

  40. Dor PJM, Fix JA (2000) In vitro determination of disintegration time of quick-dissolve tablets using a new method. Pharm Dev Technol 5(4):575–577

    Article  CAS  PubMed  Google Scholar 

  41. Marroum PJ (2008) Setting meaningful in vitro dissolution specifications. Available via the American Pharmaceutical Review website. http://americanpharmaceuticalreview.com/ViewArticle.aspx?ContentID=3210. Accessed 06 Oct 2011

  42. Rathbone MJ, Shen J, Ogle CR, Burggraaf S, Bunt CR (2000) In vitro drug release testing of controlled release veterinary drug products. In: Rathbone MJ, Gurny R (eds) Controlled Release Veterinary Drug Delivery: Biological and Pharmaceutical Considerations, 1st edn. Elsevier, New York pp, pp 311–332

    Chapter  Google Scholar 

  43. Ahmed I, Kasraian K (2002) Pharmaceutical challenges in veterinary product development. Adv Drug Deliv Rev 54:871–882

    Article  CAS  PubMed  Google Scholar 

  44. Rathbone MJ, Martinez MN, Huynh M, Burgess D (2009) CRS/AAPS joint workshop on critical variables in the in vitro and in vivo performance of parenteral sustained-release products. Dissolution Technol 16(2):55–56

    Article  Google Scholar 

  45. Shah V (2005) Establishing dissolution specification current CMC practice. Advisory Committee for Pharmaceutical Sciences. Available via FDA website. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4137S1_04_Shah.ppt. Accessed 06 Oct 2011

  46. Burgess DJ, Crommelin DJA, Hussain AS, Chen M (2004) Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS Pharm Sci 6(1):1–12

    Article  Google Scholar 

  47. United States Food and Drug Administration (2008) Guidance for industry. Orally disintegrating tablets. Center for Drug Evaluation and Research (CDER), Rockville, MD

    Google Scholar 

  48. The European Agency for the Evaluation of Medicinal Products (2004) Note for guidance on the quality of modified release dosage forms for veterinary use. The European Agency for the Evaluation of Medicinal Products, London

    Google Scholar 

  49. Sunkara G, Chilukuri DM (2003) IVIVC: an important tool in the development of drug delivery systems. Drug Deliv Technol 3(4). Accessed via journal website. http://www.drugdeliverytech.com/ME2/dirmod.asp?sid=4306B1E9C3CC4E07A4D64E23FBDB232C&nm=Back+Issues&type=Publishing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=B240FEB1DF9D435BA313EFF2E91F5AD7. Accessed 06 Oct 2011

  50. Uppoor VRS (2001) Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 72:127–132

    Article  CAS  PubMed  Google Scholar 

  51. Karalis V, Magklara E, Shah VP, Macheras P (2010) From drug delivery systems to drug release, dissolution, IVIVC, BCS, bioequivalence and biowaivers. Pharm Res 27:2018–2029

    Article  CAS  PubMed  Google Scholar 

  52. Gillespie WR (1997) Convolution-based approaches for in vitro-in vivo correlation modeling In, In Vitro-In Vivo Correlations, 1st edn. Plenum Press, New York

    Google Scholar 

  53. Rathbone MJ, Bunt CR, Ogle CR, Burggraaf S, Ogle C, Macmillan KL, Burke CR, Pickering KL (2002) Reengineering of a commercially available.bovine intravaginal insert (CIDR insert) containing progesterone. J Control Release 85:105–115

    Article  CAS  PubMed  Google Scholar 

  54. Rathbone MJ, Macmillan KL, Bunt CR, Burggraaf S, Burke C (1997) Conceptual and commercially available intravaginal veterinary drug delivery systems (invited review). Adv Drug Deliv Rev 28:363–392

    Article  PubMed  Google Scholar 

  55. Rathbone MJ, Macmillan KL, Inskeep K, Day M, Burggraaf S, Bunt CR (1997) Fertility ­regulation in cattle (invited review). J Control Release 54:117–148

    Article  Google Scholar 

  56. Rathbone MJ, Macmillan KL, Jöchle W, Boland M, Inskeep K (1998) Controlled release products for the control of the estrous cycle in cattle, sheep, goats, deer, pigs and horses (invited review). Crit Rev Ther Drug Carrier Syst 15:285–380

    Article  CAS  PubMed  Google Scholar 

  57. Rathbone MJ, Kinder JE, Fike K, Kojima F, Clopton D, Ogle CR, Bunt CR (2001) Recent advances in bovine reproductive endocrinology and physiology and their impact on drug delivery system design for the control of the estrous cycle in cattle. Adv Drug Deliv Rev 50:277–320

    Article  CAS  PubMed  Google Scholar 

  58. Rathbone MJ, Macmillan KL (2004) Applications of controlled release science and technology: progesterone. Cont Rel Newsl 21:8–9

    Google Scholar 

  59. Hanson WA (1982) Handbook of Dissolution Testing. Pharmaceutical Technology Publications, Springfield, USA

    Google Scholar 

  60. Banakar UV (1991) Factors that Influence Dissolution Testing. In: Banakar UV (ed) Pharmaceutical Dissolution Testing, Chapter 5. Marcel Dekkar, Inc., New York, USA, pp 133–187

    Chapter  Google Scholar 

  61. Ogle CR. (1999) Design, development and optimisation of veterinary intravaginal controlled release drug delivery systems. PhD Thesis, University of Waikato

    Google Scholar 

  62. Rathbone MJ, Bunt CR, Ogle CR, Burggraaf S, Ogle C, Macmillan KL, Pickering KL (2002) Development of an injection molded poly (ε-caprolactone) intravaginal insert for the delivery of progesterone to cattle. J Control Release 85:61–71

    Article  CAS  PubMed  Google Scholar 

  63. Bunt CR, Rathbone MJ, Burggraaf S, Ogle CR (1997) Development of a QC release assessment method for a physically large veterinary product containing a highly water insoluble drug and the effect of formulation variables upon release. Proc Int Symp Control Release Bioact Mater 24:145–146

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Merck Animal Health, Summit, NJ, USA

    Shannon Higgins-Gruber & Jay C. Brumfield

  2. International Medical University, Kuala Lumpur, Malaysia

    Michael J. Rathbone

Authors
  1. Shannon Higgins-Gruber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. Rathbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jay C. Brumfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shannon Higgins-Gruber .

Editor information

Editors and Affiliations

  1. Division of Pharmacy, International Medical University, #126 Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur, 57000, Malaysia

    Michael J. Rathbone

  2. , New Zealand's National School of Pharmac, University of Otago, Dunedin, 9054, New Zealand

    Arlene McDowell

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Controlled Release Society

About this chapter

Cite this chapter

Higgins-Gruber, S., Rathbone, M.J., Brumfield, J.C. (2013). In Vitro Drug Release Testing of Veterinary Pharmaceuticals. In: Rathbone, M., McDowell, A. (eds) Long Acting Animal Health Drug Products. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4439-8_9

Download citation

Publish with us

Policies and ethics

Search

Navigation